IBM Watson Hard At Work: New Breakroughs Transform Quality Care for Patients

NEW YORK CITY - 08 Feb 2013: IBM (NYSE: IBM), WellPoint, Inc. (NYSE: WLP) and Memorial Sloan-Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence based medicine.

Manoj Saxena, left, IBM General Manager, Watson Solutions, Mark Kris, MD, Chief of Thoracic Oncology, Memorial Sloan-Kettering Cancer Center, and Lori Beer, WellPoint's Executive Vice President of Specialty Businesses and Information Technology use the new Watson-based cognitive computing product for oncology. IBM, Memorial Sloan-Kettering and WellPoint introduced the first commercially based products based on Watson at an IBM healthcare forum in New York City, Friday, February 8, 2013. (Feature Photo Service)

The American Cancer Society projects that 1.6 million new cancer cases will be diagnosed in the U.S. this year alone. Studies suggest that the complexities associated with healthcare have caused one in five health care patients to receive a wrong or incomplete diagnosis. These statistics, coupled with a data explosion of medical information that is doubling every five years, represents an unprecedented opportunity for the health care industry and next generation cognitive computing systems, to combine forces in new ways to improve how medicine is taught, practiced and paid for.

For more than a year, IBM has partnered separately with WellPoint and Memorial Sloan-Kettering to train Watson in the areas of oncology and utilization management. During this time, clinicians and technology experts spent thousands of hours teaching Watson how to process, analyze and interpret the meaning of complex clinical information using natural language processing, all with the goal of helping to improve health care quality and efficiency.

"IBMs work with WellPoint and Memorial Sloan-Kettering Cancer Center represents a landmark collaboration in how technology and evidence based medicine can transform the way in which health care is practiced," said Manoj Saxena, IBM General Manager, Watson Solutions. "These breakthrough capabilities bring forward the first in a series of Watson-based technologies, which exemplifies the value of applying big data and analytics and cognitive computing to tackle the industries most pressing challenges."

Advancing Oncology Through Evidence Based Medicine

To date, Watson has ingested more than 600,000 pieces of medical evidence, two million pages of text from 42 medical journals and clinical trials in the area of oncology research. Watson has the power to sift through 1.5 million patient records representing decades of cancer treatment history, such as medical records and patient outcomes, and provide to physicians evidence based treatment options all in a matter of seconds.

In less than a year, Memorial Sloan-Kettering has immersed Watson in the complexities of cancer and the explosion of genetic research which has set the stage for changing care practices for many cancer patients with highly specialized treatments based on their personal genetic tumor type.

Starting with 1,500 lung cancer cases, Memorial Sloan-Kettering clinicians and analysts are training Watson to extract and interpret physician notes, lab results and clinical research, while sharing its profound expertise and experiences in treating hundreds of thousands of patients with cancer.

It can take years for the latest developments in oncology to reach all practice settings. The combination of transformational technologies found in Watson with our cancer analytics and decision-making process has the potential to revolutionize the accessibility of information for the treatment of cancer in communities across the country and around the world, said Craig B.Thompson, M.D., President of Memorial Sloan-Kettering Cancer Center. Ultimately, we expect this comprehensive, evidence-based approach will profoundly enhance cancer care by accelerating the dissemination of practice-changing research at an unprecedented pace.

The Maine Center for Cancer Medicine and WESTMED Medical Group are the first two early adopters of the capability. Their oncologists will begin testing the product and providing feedback to WellPoint, IBM and Memorial Sloan-Kettering to improve usability.

Speeding Utilization Management to Improve Patient Care

Throughout WellPoint's utilization management pilot, Watson absorbed more than 25,000 test case scenarios and 1,500 real-life cases, and gained the ability to interpret the meaning and analyze queries in the context of complex medical data and human and natural language, including doctors notes, patient records, medical annotations and clinical feedback. In addition, more than 14,700 hours of hands-on training was spent by nurses who meticulously trained Watson. Watson continues to learn while on the job, much like a medical resident, while working with the WellPoint nurses who originally conducted its training.

Watson started processing common, medical procedure requests by providers for members in WellPoint affiliated health plans in December, and was expanded to include five provider offices in the Midwest. Watson will serve as a powerful tool to accelerate the review process between a patients physician and their health plan.

The health care industry must drive transformation through innovation, including harnessing the latest technology that will ultimately benefit the health care consumer, said Lori Beer, WellPoint's executive vice president of Specialty Businesses and Information Technology. We believe that WellPoint's data, knowledge and extensive provider network, combined with the IBM Watson tec

LINK:	http://www-03.ibm.com/press/uk/en/pressrelease/40385.wss...
	See more stories from ibm

Most recent headlines